Sickle cell disease is an inherited blood disorder characterized by chronic hemolytic anemia, recurrent vaso-occlusive events, and progressive organ damage. Current disease-modifying therapies can reduce symptoms, but they do not address the underlying genetic cause. Allogeneic hematopoietic stem-cell transplantation offers a potential cure, but its use is limited by donor availability and the risk of graft-versus-host disease.
Recent advances in gene therapy have shifted focus toward autologous approaches that avoid donor-related risks. Several strategies aim to reduce sickling by increasing fetal hemoglobin, a form of hemoglobin that, at sufficiently high levels, is associated with inhibition of sickle hemoglobin polymerisation and reduced disease severity. Natural models such as hereditary persistence of fetal hemoglobin confirm this, showing that sustained high levels can substantially attenuate disease severity.
In this study, Hanna et al. (2026) evaluate renizgamglogene autogedtemcel (reni-cel), an investigational CRISPR-Cas12a gene-edited therapy designed to reactivate fetal hemoglobin1. Unlike approaches that target regulatory enhancers, reni-cel edits the promoters of the γ-globin genes HBG1 and HBG2 to disrupt binding of the BCL11A repressor. The phase 1–2 RUBY trial reports early clinical and molecular outcomes in patients with severe sickle cell disease following a single infusion of edited autologous stem cells.
The RUBY study is a phase 1–2, multicenter, open-label, single-group trial evaluating reni-cel in patients with severe sickle cell disease. Twenty-eight patients received a single infusion of CRISPR-Cas12a–edited autologous CD34+ cells following myeloablative busulfan conditioning. The study was terminated early, and results are based on a non-prespecified descriptive analysis.
Engraftment was achieved in 27 of 28 patients, with median times of 23 days for neutrophils and 25 days for platelets. Editing efficiency was high at infusion and remained stable over time, with a mean on-target editing of ~77% at release and sustained levels of ~74 to 86%. No off-target editing was detected based on analysis of six drug-product batches.
Treatment led to marked hematologic improvement. Total hemoglobin increased from 9.8 g/dL at baseline to 13.8 g/dL by month 6 and was maintained thereafter. Fetal hemoglobin rose from 2.5% to approximately 48%, remained above 40%, and showed near-uniform expression, with F cells reaching approximately 99%. Markers of hemolysis improved over time, indicating reduced red-cell destruction.
Clinical outcomes showed a substantial reduction in disease activity. Patients experienced a mean of 4.6 severe vaso-occlusive events per year before treatment. After reni-cel infusion, 27 of 28 patients had no severe events, and no non-severe events were reported, though the short and variable observation period limits interpretation.
All patients experienced adverse events, with 96% reporting grade 3 or 4 events and 43% reporting serious adverse events. Common events included febrile neutropenia, stomatitis, and mucosal inflammation, most occurring within the first three months. Overall, the safety profile was broadly consistent with myeloablative busulfan conditioning and autologous stem-cell transplantation, though two serious adverse events were considered possibly related to reni-cel.
This study provides clinical evidence that direct promoter editing of HBG1 and HBG2 can reactivate fetal hemoglobin at levels associated with disease modification. The magnitude of HbF induction, sustained above 40% with near-uniform distribution, aligns with thresholds previously linked to reduced sickling and fewer clinical complications.
The hematologic response is not limited to a biomarker shift. The increase in total hemoglobin into the normal range, alongside improvements in hemolysis markers, indicates a broader restoration of red-cell function. The near-complete absence of vaso-occlusive events in most patients supports this, although the short follow-up period limits conclusions about durability.
From a mechanistic perspective, the results support γ-globin promoter editing as a viable alternative to enhancer-based approaches. The existing approved CRISPR therapy for sickle cell disease targets the BCL11A erythroid enhancer. In contrast, reni-cel disrupts the repressor binding site directly at the HBG1 and HBG2 promoters. This distinction matters because it demonstrates that multiple points within the same regulatory pathway can be targeted to achieve similar biological outcomes.
The study also reinforces a broader strategy in genetic medicine: replicating benign natural variants. By mimicking hereditary persistence of fetal hemoglobin, the therapy leverages an established protective phenotype rather than introducing an entirely novel function. Whether this reduces biological uncertainty remains to be established, but grounding the therapy in a known benign variant provides a more conservative starting point than introducing novel constructs.
At the same time, the data highlight the limits of early-phase evidence. The analysis is descriptive, the cohort is small, and only a subset of patients has follow-up beyond one year. The absence of a comparator makes it difficult to separate treatment effects from the effects of conditioning and transplantation, particularly given their known impact on disease activity.
Taken together, the findings show that high-efficiency editing of γ-globin promoters can produce rapid and clinically meaningful changes in severe sickle cell disease, but they do not yet establish long-term efficacy, safety, or comparative advantage over existing gene therapies.
This study reports strong early signals, but several constraints limit how far the findings can be taken. The cohort is small, follow-up is short, and the analysis is descriptive rather than based on prespecified endpoints. Only a subset of patients has been observed beyond one year, so the durability of hemoglobin normalisation and long-term safety remain uncertain.
The treatment model also retains the core limitations of current autologous gene therapies. Myeloablative conditioning with busulfan drives much of the observed toxicity, with high rates of grade 3 or 4 adverse events and a need for specialist transplant infrastructure. These requirements restrict access to a small number of centres and complicate broader clinical adoption, even if efficacy is confirmed.
A more immediate issue is strategic rather than scientific. Development of reni-cel was discontinued due to a reassessment of clinical development priorities, including a shift toward in vivo gene-editing approaches, rather than any concerns about safety or efficacy. This decision highlights a key tension in the field: ex vivo therapies can produce strong clinical effects, but their complexity and cost may limit their long-term viability compared with approaches that avoid cell collection, conditioning, and transplantation.
The results still have clear value. They validate the HBG1 and HBG2 promoters as effective targets for fetal hemoglobin reactivation and show that high editing efficiency can be achieved and maintained in patients. This supports ongoing efforts to translate the same biological mechanism into less intensive treatment formats.
The direction of travel is clear. Future work is likely to focus on reducing treatment burden while preserving efficacy, through strategies such as non-myeloablative conditioning or direct in vivo editing. In that context, this study serves less as a final product and more as a proof of principle for where the field is heading.